

AUG. 31. 2004 11:40AM

AVENTIS US PAT DEPT

**RECEIVED**  
**CENTRAL FAX CENTER**

NO. 6953 P. 2

**PATENT**

AUG 31 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**MICHAELIS, et al.**

Examiner:

Art Unit: 1646

Application No.: 10/773,772

Filed: 6 February 2004

Title: **THE USE OF ANTAGONISTS OF THE  
BRADYKININ B2 RECEPTOR FOR THE  
TREATMENT OF OSTEOARTHRISIS**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,  
at (703) 746-9195, on

August 31, 2004

Date of Transmission

Signature

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the  
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the title that should read "THE USE OF ANTAGONISTS OF THE  
BRADYKININ B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHRISIS" as shown on the  
enclosed copy of the Application Data Sheet, not "THE USE OF ANTAGONISTS OF THE BRADYKININ  
B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHRISIS".

The error on the Filing Receipt is not due to the Applicant; therefore, no additional fees should be  
required, however the Commissioner is hereby authorized to charge any fees which are required by  
this paper to Deposit Account 18-1982.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065  
Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2003/0008 US NP



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1430  
 Alexandria, Virginia 22313-1430  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/773,772	02/06/2004	1646	770	DEAV2003/0008USNP		7	1

CONFIRMATION NO. 7891

05487

ROSS J. OEHLER  
 AVENTIS PHARMACEUTICALS INC.  
 ROUTE 202-206  
 MAIL CODE: D303A  
 BRIDGEWATER, NJ 08807

## FILING RECEIPT

\*OC000000012584600\*

COMPUTER ENTERED

Date Mailed: 05/11/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-8195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Martin Michaelis, Frankfurt, GERMANY;  
 Karl Rudolphi, Mainz, GERMANY;

## Assignment For Published Patent Application

Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY;

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/480,246 06/20/2003

## Foreign Applications

GERMANY DE10304994.0-41 02/07/2003

If Required, Foreign Filing License Granted: 05/10/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**Title**

Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthritis

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).